Advanced hepatocellular cancer: The current state of future research Journal Article


Authors: Connell, L. C.; Harding, J. J.; Abou-Alfa, G. K.
Article Title: Advanced hepatocellular cancer: The current state of future research
Abstract: Hepatocellular carcinoma is a common malignancy worldwide, rapidly rising in incidence. While there have been some developments in advancing therapeutic options in this disease, these have admittedly been modest to date, and as a result, this is a patient population with an inherently poor prognosis. Currently, sorafenib remains the only established systemic therapy proven to increase the overall survival of patients with advanced disease. The approval of sorafenib in 2007 ushered in the era of targeted therapies. Several phase 2 and 3 clinical trials have failed however to improve on sorafenib in the first-line setting, and no single agent has been demonstrated to impact outcomes after sorafenib failure. Having reached somewhat of an impasse in terms of drug development in hepatocellular carcinoma, enthusiasm in the field has moved toward innovative approaches such as molecular characterization and immunotherapy in an attempt to impact survival. This review highlights the current endeavors in terms of experimental research for patients with advanced hepatocellular carcinoma. © 2016, Springer Science+Business Media New York.
Keywords: hepatocellular carcinoma; sorafenib; doxorubicin; immunotherapy; targeted therapy; everolimus; angiogenic; tremelimumab; cabozantinib; nivolumab; tivantinib; pegylated arginine deiminase (adi-peg 20); medi4736
Journal Title: Current Treatment Options in Oncology
Volume: 17
Issue: 8
ISSN: 1527-2729
Publisher: Springer  
Date Published: 2016-08-01
Start Page: 43
Language: English
DOI: 10.1007/s11864-016-0415-3
PROVIDER: scopus
PUBMED: 27344158
DOI/URL:
Notes: Review -- Export Date: 2 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    250 Harding
  2. Ghassan Abou-Alfa
    568 Abou-Alfa
  3. Louise Catherine Connell
    45 Connell